Cancer Policy FDA’s OCE publishes three final guidances to increase clinical trial enrollment July 31, 2026Vol.52 No.30By Jacquelyn Cobb
Drugs & Targets After two CRLs, FDA advisory committee votes in favor of Replimune’s melanoma drug July 31, 2026Vol.52 No.30
Podcast Hegseth offers soldiers testosterone and FDA loosens safety warnings. Is the science there? July 29, 2026
Regulatory News Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warningsExperts caution the move amounts to a “huge, unregulated, natural experiment” July 24, 2026Vol.52 No.29By Claire Marie Porter
Drugs & Targets FDA approves Jideytro for previously treated ROS1-positive non-small cell lung cancer July 24, 2026Vol.52 No.29
Drugs & Targets FDA grants priority review for Talzenna + Xtandi combo in earlier prostate cancer July 24, 2026Vol.52 No.29
Regulatory News FDA final guidance on psychedelics opens the door to psycho-oncology researchGuidance permits treatment without psychotherapy, alarming scientists, advocates July 17, 2026Vol.52 No.28By Sara Willa Ernst
Cancer Policy House Energy & Commerce hearing focuses on America’s leadership in biomedical research, examines FDA role July 17, 2026Vol.52 No.28By Claire Marie Porter
Drugs & Targets FDA approves Padcev + Keytruda for muscle-invasive bladder cancer regardless of cisplatin eligibility July 17, 2026Vol.52 No.28
